"But I didn't drink!": What to do with discordant phosphatidylethanol results.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
25 Jul 2023
25 Jul 2023
Historique:
received:
31
05
2023
accepted:
08
07
2023
pubmed:
24
7
2023
medline:
24
7
2023
entrez:
24
7
2023
Statut:
aheadofprint
Résumé
Liver transplantation (LT) teams must be adept at detecting, evaluating, and treating patients' alcohol use, given its prominence among psychological and behavioral phenomena which cause and contribute to liver diseases. Phosphatidylethanol (PEth) is a highly useful alcohol biomarker increasingly recommended for routine use in hepatology and LT. PEth is unique among alcohol biomarkers because of its wide detection window, high sensitivity and specificity, and the correlation of its numerical value with different patterns of alcohol use. Alongside myriad clinical opportunities in hepatology and LT, PEth also confers numerous challenges: little guidance exists about its clinical use; fearing loss of LT access and the reactions of their clinicians and families, candidates and recipients are incentivized to conceal their alcohol use; and liver clinicians report lack of expertise diagnosing and treating substance-related challenges. Discordance between patient self-reported alcohol use and toxicology is yet another common and particularly difficult circumstance. This article discusses the general toxicological properties of PEth; explores possible scenarios of concordance and discordance among PEth results, patient history, and self-reported drinking; and provides detailed clinical communication strategies to explore discordance with liver patients, a key aspect of its use.
Identifiants
pubmed: 37486958
doi: 10.1097/LVT.0000000000000223
pii: 01445473-990000000-00211
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Louvet A, Labreuche J, Moreno C, Vanlemmens C, Moirand R, Féray C, et al. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. Lancet Gastroenterol Hepatol. 2022;7:416–25.
Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, et al. Patterns of alcohol use after early liver transplantation for alcoholic hepatitis. Clin Gastroenterol Hepatol. 2022;20:409–18. e5.
Lee BP, Vittinghoff E, Dodge JL, Cullaro G, Terrault NA. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med. 2019;179:340–8.
Webzell I, Ball D, Bell J, Sherwood RA, Marsh A, O’grady JG, et al. Substance use by liver transplant candidates: an anonymous urinalysis study. Liver Transpl. 2011;17:1200–4.
Segal A, Adkins E, Fatabhoy M, Bryce K, Gonzalez HC, Miller-Matero LR. Utility of phosphatidylethanol testing in liver transplant evaluation: examining concordance to self-reported alcohol use. Liver Transpl. 2023;29:456–8.
Donnadieu-Rigole H, Olive L, Nalpas B, Winter A, Ursic-Bedoya J, Faure S, et al. Follow-up of alcohol consumption after liver transplantation: interest of an addiction team? Alcohol Clin Exp Res. 2017;41:165–70.
Andresen-Streichert H, Beres Y, Weinmann W, Schrock A, Muller A, Skopp G, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017;30:611–620.
Staufer K, Huber-Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer T-M, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918–30.
Faulkner CS, White CM, Manatsathit W, Lamb B, Vatsalya V, McClain CJ, et al. Positive blood phosphatidylethanol concentration is associated with unfavorable waitlist‐related outcomes for patients medically appropriate for liver transplantation. Alcohol Clin Exp Res. 2022;46:581–8.
Fleming MF, Smith MJ, Oslakovic E, Lucey MR, Vue JX, Al-Saden P, et al. Phosphatidylethanol detects moderate-to-heavy alcohol use in liver transplant recipients. Alcohol Clin Exp Res. 2017;41:857–62.
Piano MR, Tiwari S, Nevoral L, Phillips SA. Phosphatidylethanol levels are elevated and correlate strongly with AUDIT scores in young adult binge drinkers. Alcohol Alcohol. 2015;50:519–25.
Luginbühl M, Weinmann W, Butzke I, Pfeifer P. Monitoring of direct alcohol markers in alcohol use disorder patients during withdrawal treatment and successive rehabilitation. Drug Test Anal. 2019;11:859–69.
Nguyen VL, Haber PS, Seth D. Applications and challenges for the use of phosphatidylethanol testing in liver disease patients (mini review). Alcohol Clin Exp Res. 2018;42:238–43.
Stöth F, Weinmann W, Soravia LM, Pfeifer P. Evaluation of phosphatidylethanol elimination in alcohol use disorder patients undergoing withdrawal treatment. Alcohol Alcohol. 2023;58:266–73.
Simon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regul Toxicol Pharmacol. 2018;94:163–71.
Ulwelling W, Smith K. The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines. J Forensic Sci. 2018;63:1634–40..
Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014;38:1706–11.
Matthews LA, Musto JA, Deiss-Yehiely N, Daniel KE, Lightbourn C, Garvey M, et al. Psychosocial assessment in liver transplantation (LT): an analysis of short-term outcomes. Hepatol Commun. 2023;7:e0017.
Afshar M, Burnham EL, Joyce C, Clark BJ, Yong M, Gaydos J, et al. Cut‐point levels of phosphatidylethanol to identify alcohol misuse in a mixed cohort including critically ill patients. Alcohol Clin Exp Res. 2017;41:1745–53.
Schröck A, Wurst FM, Thon N, Weinmann W. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test – C (AUDIT-C). Drug Alcohol Depend. 2017;178:80–86.
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101:1546–60.
Selim R, Zhou Y, Rupp LB, Trudeau S, Naffouj S, Shamaa O, et al. Availability of PEth testing is associated with reduced eligibility for liver transplant among patients with alcohol-related liver disease. Clin Transplant. 2022;36:e14595.
Asrani SK, Trotter J, Lake J, Ahmed A, Bonagura A, Cameron A, et al. Meeting report: the Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis. Liver Transpl. 2020;26:127–40.
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol‐related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019.
Jowsey-Gregoire S, Jannetto PJ, Jesse MT, Fleming J, Winder GS, Balliet W, et al. Substance use screening in transplant populations: Recommendations from a consensus workgroup. Transplant Rev. 2022;36:100694.
Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11:163–73.
Jinjuvadia R, Jinjuvadia C, Puangsricharoen P, Chalasani N, Crabb DW, Liangpunsakul S, et al. Concomitant psychiatric and nonalcohol-related substance use disorders among hospitalized patients with alcoholic liver disease in the United States. Alcohol Clin Exp Res. 2018;42:397–402.
Castillo-Carniglia A, Keyes KM, Hasin DS, Cerdá M. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiatry. 2019;6:1068–80.
Reisfield GM, Teitelbaum SA, Jones JT, Mason D, Bleiweis M, Lewis B. Blood phosphatidylethanol (PEth) concentrations following intensive use of an alcohol-based hand sanitizer. J Anal Toxicol. 2023;46:979–90.
Reisfield GM, Teitelbaum SA, Jones JT. Persistent urinary ethyl sulfate in the absence of urinary ethyl glucuronide in a patient with alcohol use disorder who claimed abstinence. J Anal Toxicol. 2020;44:623–66.
Hahn JA, Murnane PM, Vittinghoff E, Muyindike WR, Emenyonu NI, Fatch R, et al. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta‐analysis. Alcohol Clin Exp Res. 2021;45:1166–87.
Aboutara N, Jungen H, Szewczyk A, Müller A, Iwersen‐Bergmann S. PEth 16: 0/18: 1 and 16: 0/18: 2 after consumption of low doses of alcohol—a contribution to cutoff discussion. Drug Test Anal 2023;15:104–14.
Bhavsar‐Burke I, Guardiola JJ, Holden JH. Is blood transfusion a means of false positive phosphatidylethanol testing? Liver Transpl. 2021;28:138–9.
Halegoua‐De Marzio DL, Herrine SK. Training the next generation of hepatologist: what will they need to know? Clin Liver Dis (Hoboken). 2015;5:129–131.
Winder GS, Clifton EG, Perumalswami P, Mellinger JL. The art of interprofessional psychosocial communication: optimizing patient interfaces with psychiatric specialists in liver transplantation. Transplant Rev. 2022;36:100728.
Im GY, Mellinger JL, Winters A, Aby ES, Lominadze Z, Rice J, et al. Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver Diseases alcohol-associated liver disease special interest group. Clin Gastroenterol Hepatol. 2021;19:2407–16. e8.
Secunda K, Gordon EJ, Sohn MW, Shinkunas LA, Kaldjian LC, Voigt MD, et al. National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl. 2013;19:395–403.
Zhu J, Chen P-Y, Frankel M, Selby RR, Fong T-L. Contemporary policies regarding alcohol and marijuana use among liver transplant programs in the United States. Transplantation. 2018;102:433–9.
Volk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med. 2011;155:503–8.
Schomerus G, Leonhard A, Manthey J, Morris J, Neufeld M, Kilian C, et al. The stigma of alcohol-related liver disease and its impact on healthcare. J Hepatol. 2022;77:516–24.
Neuberger J. Public and professional attitudes to transplanting alcoholic patients. Liver Transpl. 2007;13(11 suppl 2):S65–8.
van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013;131:23–35.
Winder GS, Clifton EG, Fernandez AC, Mellinger JL. Interprofessional teamwork is the foundation of effective psychosocial work in organ transplantation. Gen Hosp Psychiatry. 2021;69:76–80.
Winder GS, Fernandez AC, Mellinger JL. Integrated care of alcohol-related liver disease. J Clin Exp Hepatol. 2022;12:1069–82.
Deutsch-Link S, Weinberg EM, Bittermann T, McDougal M, Dhariwal A, Jones LS, et al. The Stanford integrated psychosocial assessment for transplant is associated with outcomes before and after liver transplantation. Liver Transpl. 2021;27:652–667.
Bittermann T, Mahmud N, Weinberg EM, Reddy KR. Rising trend in waitlisting for alcoholic hepatitis with more favorable outcomes than other high model for end-stage liver disease in the current era. Transplantation. 2022;106:1401–10.
Appelbaum PS. Assessment of patients’ competence to consent to treatment. N Engl J Med. 2007;357:1834–1840.
Miller WR, Rollnick S. Motivational interviewing: helping people change. Guilford Press; 2013.
ASAM Criteria: American Society of Addiction Medicine. Accessed June 2023. https://www.asam.org/asam-criteria/about-the-asam-criteria .
Winder GS, Clifton EG, Fernandez AC, MacEachern M, Andrews S, Perumalswami P, et al. Definition and measurement of alcohol-related insight in early liver transplantation for acute alcohol-associated hepatitis: a systematic review. Liver Transpl. 2023;29:757–767.
Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, et al. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154–81.
Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, et al. Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease. Hepatology. 2022;75:1026–37.